Objectives: To provide the radiology community with data to address the question: "Compared with peer institutions, is my institution efficiently using its electrocardiographic (ECG) gating and cerebral perfusion-capable computed tomography (CT) scanners?", Methods: In this retrospective study, we analyze 6 months of scanner utilization data from 62 institutions (299 locations, 507 scanners) to identify scanners capable of performing ECG gating and perfusion CT studies. We report the number of ECG gating/perfusion-capable scanners and locations as a function of the total number of locations and scanners in each institution. We additionally regress the number of ECG-gated and perfusion examinations on (1) the number of locations/scanners capable of performing these examinations and (2) the fraction of the institution's CT examination volume that requires ECG gating or perfusion. We provide look-up tables so an institution can compare its ECG-gated/perfusion examination volume to other institutions with similar ECG-gated/perfusion examination fractions and capable scanners., Results: We detected an effect of both ECG-gating examination fraction and the number of ECG gating-capable scanners on ECG-gated examination volume ( χ21 = 77.5 [ P < 0.001] and χ21 = 64.2 [ P < 0.001], respectively). Similar results were obtained for perfusion examination fraction and perfusion-capable scanners as they relate to perfusion examination volume ( χ21 = 51.6 [ P < 0.001] and χ21 = 45.2 [ P < 0.001], respectively). The number of ECG gating/perfusion-capable scanners and locations within an institution were found to positively correlate with both the total number of locations and scanners within an institution ( P < 0.001 for all hypothesis tests)., Conclusions: The study provides multi-institutional data on ECG gating and perfusion examination volumes that can be used to inform CT purchasing decisions., Competing Interests: S.D.R. received prior research support from GE Healthcare and has a patent “Apparatus for Tomography Repeat Rate/Reject Rate Capture” licensed by Qaelum NV and Flowhow. M.G.L. is chief of Clinical and Research CT, received prior grant funding from Philips and Ethicon, and her spouse is a consultant to Elephas Bio. J.H. is cofounder and CEO of Imalogix LLC. T.P.S. is director of Clinical Operations, CT Protocol Project and is on the medical advisory board of Imalogix LLC. He receives research support, is a consultant, and is on an advisory board to GE Healthcare; is a consultant to AiDoc, AstoCT LLC, ALARA Medical, and Flowhow; and has a patent “Apparatus for Tomography Repeat Rate/Reject Rate Capture” licensed by Qaelum NV and Flowhow. G.M.G. declares no conflict of interest., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)